Session Information
Date: Tuesday, September 24, 2019
Session Title: Parkinsonisms and Parkinson-Plus
Session Time: 1:45pm-3:15pm
Location: Agora 3 West, Level 3
Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (HSA) (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related disorders.
Background: Diagnosis of PD is based on only clinical symptoms, including parkinsonism, REM-sleep behavior disorder (RBD), hyposmia and autonomic dysfunction. Therefore, biological biomarkers might be useful for not only diagnosing but reflecting the pathology resulting the possibility of treatment of PD. It is well known that oxidative stress is related to pathomechanism of PD, parkin/PARK2 is closely associated with mitochondrial quality control as well. Therefore, we hypothesized that %HNA might be a robust biomarker of a hyperoxidative state in iPD and PARK2.
Method: This prospective studyenrolled 216 iPD patients (age 66.0 ±0.63; male 102), 15 PARK2 patients (age 52.1 ±4.56; male 6), and 83 healthy controls (age 63.6 ±1.02; male 39). The patients take blood samples in the morning with a non-consumption of any diet. HNA were analyzed modified high performance liquid chromatography (HPLC), and were evaluated with other parameters.
Results: %HNA was statistically correlated with increasing age in each group. %HNA level in iPD and PARK2 showed higher than in healthy control group (iPD 27.7 ±0.29, control 24.5 ±0.38,OR 1.260, p < 0.001; PARK2 26.3 ±1.68,control 24.5 ±0.38, OR 1.592, p < 0.001). There is statistical significant higher %HNA in early stage ofHoehn & Yahr (H&Y) staging I-II in iPD than control group. In addition, Unified Parkinson’s Disease Rating Scale part III scores, H&Y stage, disease duration, and levodopa dose did not relate to serum %HNA levels in iPD and PARK2.
Conclusion: In our study, %HNA tends to increase in iPD and PARK2 regardless of disease course and severity. Oxidative stress markers, including oxidative albumin, may be useful biomarkers for diagnosing prodromal PD and related disorders.
To cite this abstract in AMA style:
S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori. Serum non-mercaptalbumin as a potential biomarker in Parkinson’s disease and related disorders [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/serum-non-mercaptalbumin-as-a-potential-biomarker-in-parkinsons-disease-and-related-disorders/. Accessed June 14, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/serum-non-mercaptalbumin-as-a-potential-biomarker-in-parkinsons-disease-and-related-disorders/